Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients.

scientific article

Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/IJC.30500
P698PubMed publication ID27813061

P50authorRakhee VatsaQ57081396
P2093author name stringAmanjit Bal
Gurpreet Singh
Bhagwant R Mittal
Jaya Shukla
Madan Parmar
Devinder K Dhawan
Priya Bhusari
P2860cites workCleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Q25938983
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.Q27824766
Mass spectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapyQ33212260
Quantification of bifunctional diethylenetriaminepentaacetic acid derivative conjugation to monoclonal antibodies by matrix-assisted laser desorption/ionization time-of-flight mass spectrometryQ33291285
Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphomaQ33372470
Evaluating the potential of 188Re-SOCTA-trastuzumab as a new radioimmunoagent for breast cancer treatmentQ33404229
Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinomaQ33767100
In Vitro and In Vivo Pre-Clinical Analysis of a F(ab')(2) Fragment of Panitumumab for Molecular Imaging and Therapy of HER1 Positive CancersQ35162293
(64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patientsQ35266784
Labeling and Biological Evaluation of (99m)Tc-HYNIC-Trastuzumab as a Potential Radiopharmaceutical for In Vivo Evaluation of HER2 Expression in Breast Cancer.Q37100372
Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours.Q37123529
Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancerQ37626334
Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using (111)In-trastuzumab (Herceptin) Fab fragments.Q40462071
Quality control of positron emission tomography radiopharmaceuticals: An institutional experienceQ42252521
An improved method for conjugating monoclonal antibodies with N-hydroxysulfosuccinimidyl DOTA.Q43582043
64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancerQ44650607
Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imagingQ44944204
Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancerQ48252174
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline updateQ57130157
P433issue4
P407language of work or nameEnglishQ1860
P921main subjectbreast cancerQ128581
P304page(s)938-947
P577publication date2016-11-18
P1433published inInternational Journal of CancerQ332492
P1476titleDevelopment of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients
P478volume140

Reverse relations

cites work (P2860)
Q57110662Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast Cancer
Q55438401Drug conjugates—an emerging approach to treat breast cancer.
Q89622510Ovarian Cancer Targeted Theranostics
Q38691472Radioimmunoconjugates for treating cancer: recent advances and current opportunities
Q49700421Targeting HER2 in Nuclear Medicine for Imaging and Therapy
Q93103176Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC)

Search more.